Onat, AltanCan, GünayHergenç, GülayYazıcı, MehmetKarabulut, AhmetAlbayrak, Sinan2020-04-302020-04-3020070307-05651476-5497https://doi.org/10.1038/sj.ijo.0803552https://hdl.handle.net/20.500.12684/4500Karabulut, Ahmet/0000-0002-2001-9142WOS: 000247487600013PubMed: 17299378Objectives: To investigate the role of serum apolipoprotein (apo) B levels in predicting metabolic syndrome (MS), hypertension, atherogenic dyslipidemia and type II diabetes. Methods: Prospective evaluation of 1125 men and 1223 women, aged 28-74 years, participating in the survey 1997/1998 who had serum apo B determinations and were followed-up for a mean 5.9 years. Tertiles of apo B were formed by cut points by 120 and 95 mg/dl. MS was defined by modified ATPIII criteria. Results: Apo B values exhibited no significant difference among sexes. Low-density lipoprotein (LDL)-cholesterol and triglycerides were their leading determinants on linear regression analysis. By logistic regression analyses, the top versus bottom apo B tertile predicted significantly newly developing MS in both sexes separately with two-fold relative risks (RRs) (P<0.02) and the development of high triglyceride/low high-density lipoprotein-cholesterol dyslipidemia with nearly threefold RRs (P=0.001), after adjustment for waist circumference, C-reactive protein (CRP), physical activity grade and family income category. Development of hypertension was predicted only in women by the apo B top tertile (fully adjusted RR 1.71 [95% CI 1.001; 2.92]), while the significance of the prediction regarding age-adjusted diabetes in women (RR 1.86 [95% CI 1.04; 3.36]) attenuated after adjustment for the stated confounding factors. Conclusions: Apo B concentrations, which reflect the number of small, dense LDL particles in plasma, are a significant predictor of cardiometabolic risk among adults with a high prevalence of MS, independent of waist circumference and CRP.en10.1038/sj.ijo.0803552info:eu-repo/semantics/openAccessapolipoprotein Bcentral obesitydiabetes mellitusdyslipidemiahypertensionmetabolic syndromeArticle31711191125WOS:000247487600013Q1Q1